High dose methotrexate with leucovorin rescue

摘要: Methotrexate (MTX) in high doses (3 to 7.5 g/m2) with leucovorin rescue (HDMTX-LCV) can be delivered on a weekly basis setting of proper pharmacologic monitoring. Myelosuppression occurs 28 per cent the patients and 8 courses usually results from delayed MTX excretion secondary mild reversible nephrotoxicity. The incidence tumor regression was 50 head neck cancer; 59 non-Hodgkin's lymphoma; 40 small cell lung 24 breast cancer osteogenic carcinoma, for an over-all response rate 39 (70 178) disseminated cancer. HDMTX-LCV is not recommended conventional treatment metastatic because potential toxicity fact that rates cited are probably superior those which achieved by MTX. However, relative lack myelosuppression mucositis, when compared unrescued MTS, achievement therapeutic concentrations central nervous system program have led its incorporation into clinical trials combination chemotherapy.